Cefuroxime
INFEKOR
Regulatory Class: Rx
Generic Name: Cefuroxime Sodium
Formulation/s: Each vial contains 750 mg of Cefuroxime (as sodium), USP
Indications or Use: Community acquired pneumonia; acute exacerbations of chronic bronchitis; complicated Urinary Tract Infection, including pyelonephritis; cellulitis, erysipelas & wound infections; intra-abdominal infections; prophylaxis against infection in Gastrointestinal (including oesophageal), orthopaedic, gynaecological surgery (including caesarean section).
Dosage and Directions for Use: Adult & children ≥40 kg Community acquired pneumonia & acute exacerbations of chronic; cellulitis, erysipelas & wound infections; intra-abdominal infections 750 mg every 8 hrs. (IV or IM). Complicated UTI, including pyelonephritis 1.5 g every 8 hrs. (IV or IM). Severe infections 750 mg every 6 hrs. (IV) or 1.5 g every 8 hrs. (IV). Surgical prophylaxis for GI, gynecological surgery (including caesarean section) & orthopaedic operations 1.5 g w/ induction of anesthesia. May be supplemented w/ two 750 mg doses (IM) after 8 hrs. & 16 hrs. Surgical prophylaxis for CV & oesophageal operations 1.5 g w/ induction of anesthesia followed by 750 mg (IM) every 8 hrs. for a further 24 hrs. Community acquired pneumonia & acute exacerbations of chronic; cellulitis, erysipelas & wound infections; intra-abdominal infections Childn <40 kg, infants & toddlers >3 wk 30-100 mg/kg/day (IV) in 3 or 4 divided doses. 60 mg/kg/day is appropriate for most infections. Infants (birth to 3 wk) 30-100 mg/kg/day (IV) in 2 or 3 divided doses. CrCl >20 mL/min/1.73 m2 750 mg to 1.5 g tid. CrCl 10-20 mL/min/1.73 m2 & <10 mL/min/1.73 m2 750 mg twice a day. Patient on haemodialysis Further 750 mg dose should be given IV or IM at the end of each dialysis. Patient in renal failure on continuous arteriovenous haemodialysis (CAVH) or high-flux haemofiltration (HF) in intensive therapy units 750 mg twice a day.
Contraindication: Hypersensitivity to cefuroxime, cephalosporin antibiotics. History of severe hypersensitivity (e.g., anaphylactic reaction) to other type of β-lactam antibacterial agent (penicillins, monobactams & carbapenems).
Special Precaution: History of severe hypersensitivity reactions to cefuroxime, other cephalosporins or any other type of β-lactam agent. Caution to patients receiving potent diuretics (e.g., furosemide) or aminoglycosides. Monitor renal function in elderly & those w/ known pre-existing renal impairment. Avoid prolonged treatment. Not suitable for infections caused by gram negative non-fermenting bacteria. May interfere w/ a positive Coombs test. Slight interference w/ Copper reduction methods (Benedict’s, Fehling’s, clinitest). False negative result may occur in the ferricyanide test. Not formulated for intracameral use. Reports of individual cases & clusters of serious ocular adverse reactions. Na intake should be considered for patients on a controlled Na diet. Pregnancy & lactation.
Adverse Reaction: Neutropenia, eosinophilia, decreased Hb conc; transient rise in liver enzymes; skin rash, urticaria & pruritus; injection site reactions which may include pain & thrombophlebitis.
Interactions: May affect the gut flora, leading to lower estrogen reabsorption & reduced efficacy of combined OCs. Prolongs the excretion of cefuroxime & produces an elevated peak serum level of probenecid. Concomitant administration of strong-acting diuretics (e.g., furosemide) or potential nephrotoxic prep (e.g., aminoglycoside antibiotics). May increase International normalized ratio of oral anticoagulants.
Presentation/ Packaging: Powd for injection (vial) 750 mg x 1’s.
For more information, please see full product information.
